1. Home
  2. GNLX

GNLX

Genelux Corporation

Logo Genelux Corporation

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.

Founded: 2001 Country:
United States
United States
Employees: N/A City: WESTLAKE VILLAGE
Market Cap: 116.9M IPO Year: 2023
Target Price: $31.75 AVG Volume (30 days): 128.1K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.16 EPS Growth: N/A
52 Week Low/High: $4.03 - $40.98 Next Earning Date: 05-02-2024
Revenue: $170,000 Revenue Growth: -98.46%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: